Article

Oncologist Suzanne L. Topalian Describes New Melanoma Treatments

Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.

Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.

"There is more reason today than ever to be hopeful about the future of patients with melanoma," says Topalian, who serves as director of the Johns Hopkins Melanoma Program and professor of Surgery and Oncology.

She explains that some of these new treatments are tailored for patients whose cancers have certain mutations and others, such as the anti-PD1s, are broader approaches and can be effective no matter the type of mutations present in the tumor.

"It's possible that by combining those two types of strategies, that we'll have even more powerful results," she says.

Her advice for patients is to stay well informed, discuss the newest treatment options with their caregivers and to remain hopeful.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.